Catalyst Wire Dossier Catalyst Wire Dossier

Remibrutinib

remibrutinib · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

28 regulatory and trial events tracked for Remibrutinib, covering 2024-11-01 to 2026-06-12. Get the full timeline:

Most recent: Clinical Trial Results: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts [Phase 2]

See pricing